[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2174293T3 - Microesferas farmaceuticas de acido valproico para la administracion oral. - Google Patents

Microesferas farmaceuticas de acido valproico para la administracion oral.

Info

Publication number
ES2174293T3
ES2174293T3 ES97943943T ES97943943T ES2174293T3 ES 2174293 T3 ES2174293 T3 ES 2174293T3 ES 97943943 T ES97943943 T ES 97943943T ES 97943943 T ES97943943 T ES 97943943T ES 2174293 T3 ES2174293 T3 ES 2174293T3
Authority
ES
Spain
Prior art keywords
valproic acid
hydrogen
oral administration
pharmaceutical microspheres
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97943943T
Other languages
English (en)
Inventor
Christian Langlois
Jean-Yves Lanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2174293T3 publication Critical patent/ES2174293T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A MICROESFERAS FARMACEUTICAS QUE CONTIENEN, COMO PRINCIPIO ACTIVO, UNA MEZCLA DE ACIDO VALPROICO Y UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN ASOCIACION CON UN SOPORTE MATRICIAL ELEGIDO ENTRE ESTERES DE GLICEROLES, ACEITES HIDROGENADOS, POLIETILENOGLICOLES ESTERIFICADOS, CERAS Y SUS MEZCLAS.
ES97943943T 1996-10-07 1997-10-03 Microesferas farmaceuticas de acido valproico para la administracion oral. Expired - Lifetime ES2174293T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612201A FR2754177B1 (fr) 1996-10-07 1996-10-07 Microspheres pharmaceutiques d'acide valproique pour administration orale

Publications (1)

Publication Number Publication Date
ES2174293T3 true ES2174293T3 (es) 2002-11-01

Family

ID=9496427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97943943T Expired - Lifetime ES2174293T3 (es) 1996-10-07 1997-10-03 Microesferas farmaceuticas de acido valproico para la administracion oral.

Country Status (40)

Country Link
US (3) US20020001598A1 (es)
EP (1) EP0956010B1 (es)
JP (1) JP3523270B2 (es)
KR (1) KR100334687B1 (es)
CN (1) CN100367945C (es)
AR (1) AR013613A1 (es)
AT (1) ATE216228T1 (es)
AU (1) AU731235B2 (es)
BR (1) BR9712268A (es)
CA (1) CA2267096C (es)
CO (1) CO4900080A1 (es)
CZ (1) CZ288876B6 (es)
DE (1) DE69712100T2 (es)
DK (1) DK0956010T3 (es)
DZ (1) DZ2316A1 (es)
EE (1) EE03744B1 (es)
EG (1) EG24070A (es)
ES (1) ES2174293T3 (es)
FR (1) FR2754177B1 (es)
HK (1) HK1021939A1 (es)
HR (1) HRP970537B1 (es)
HU (1) HU225103B1 (es)
ID (1) ID24596A (es)
IL (1) IL128745A (es)
IS (1) IS1985B (es)
ME (1) ME00664B (es)
MY (1) MY120521A (es)
NO (1) NO325723B1 (es)
NZ (1) NZ334399A (es)
PL (1) PL190105B1 (es)
PT (1) PT956010E (es)
RS (1) RS49602B (es)
RU (1) RU2177315C2 (es)
SI (1) SI0956010T1 (es)
SK (1) SK282113B6 (es)
TR (1) TR199900789T2 (es)
TW (1) TW508251B (es)
UY (1) UY24738A1 (es)
WO (1) WO1998015268A1 (es)
ZA (1) ZA978954B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100660A (et) * 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
CA2508855A1 (en) * 2002-12-16 2004-07-01 Frank Slade Abbott Valproic acid analogues and pharmaceutical compositions thereof
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
JP2008512386A (ja) * 2004-09-07 2008-04-24 オーファン メディカル，インコーポレイティド 改良型ｇｈｂ組成物
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
CN101543631B (zh) * 2008-03-28 2012-01-11 沈阳兴齐制药有限公司 含蜂蜡的微球基质、含有它的药物组合物及其用途
EP2431031B1 (en) * 2009-05-12 2016-06-08 Amorepacific Corporation Composition for preventing hair loss or for stimulating hair growth
PE20160850A1 (es) * 2013-11-13 2016-09-23 Tillotts Pharma Ag Sistema multiparticulado para administrar drogas
CN104013596A (zh) * 2014-05-16 2014-09-03 安士制药（中山）有限公司 一种丙戊酸软胶囊及其制备方法
CN105456217A (zh) * 2014-08-27 2016-04-06 捷思英达医药技术（上海）有限公司 一种双丙戊酸钠缓释剂组合物及其制备方法
EP3675267A4 (en) 2017-08-24 2021-05-19 Mitsui Chemicals, Inc. WATER-FREE ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY
KR20200035095A (ko) 2017-08-24 2020-04-01 미쓰이 가가쿠 가부시키가이샤 리튬 이차 전지 및 비수 전해액
FR3087445B1 (fr) * 2018-10-19 2021-12-17 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition lipidique pour l'encapsulation d'une substance active et permettant le controle de la vitesse de liberation de ladite substance active
CN111012753A (zh) * 2020-01-07 2020-04-17 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法
CN112274499A (zh) * 2020-11-16 2021-01-29 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2293974A1 (fr) * 1973-03-02 1976-07-09 Kaltenbach Roger Procede et dispositif pour la granulation reguliere de divers produits
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
FR2682677A1 (fr) * 1991-10-17 1993-04-23 Sanofi Elf Complexe forme de l'acide propyl-2 pentene-2 ouique (e) et de son sel de sodium, sa preparation et compositions pharmaceutiques le contenant.
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5690959A (en) * 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
ZA978954B (en) 1999-04-07
NO325723B1 (no) 2008-07-07
HUP9903855A3 (en) 2000-06-28
RS49602B (sr) 2007-06-04
DK0956010T3 (da) 2002-08-12
EP0956010B1 (fr) 2002-04-17
WO1998015268A1 (fr) 1998-04-16
EG24070A (en) 2008-05-11
YU17899A (sh) 2000-03-21
JP3523270B2 (ja) 2004-04-26
AR013613A1 (es) 2001-01-10
EP0956010A1 (fr) 1999-11-17
TR199900789T2 (xx) 1999-07-21
US20060263437A1 (en) 2006-11-23
KR100334687B1 (ko) 2002-04-27
HUP9903855A2 (hu) 2000-05-28
DE69712100T2 (de) 2002-11-28
SK36499A3 (en) 2000-12-11
CO4900080A1 (es) 2000-03-27
NO991613D0 (no) 1999-04-06
PL332249A1 (en) 1999-08-30
EE9900140A (et) 1999-12-15
IS4996A (is) 1999-03-11
CA2267096A1 (fr) 1998-04-16
CN1232391A (zh) 1999-10-20
US20020001598A1 (en) 2002-01-03
PT956010E (pt) 2002-08-30
UY24738A1 (es) 2001-05-31
SK282113B6 (sk) 2001-11-06
CN100367945C (zh) 2008-02-13
NZ334399A (en) 2000-05-26
CZ121199A3 (cs) 1999-08-11
CA2267096C (fr) 2003-09-16
BR9712268A (pt) 1999-08-31
PL190105B1 (pl) 2005-10-31
HU225103B1 (en) 2006-06-28
KR20000048828A (ko) 2000-07-25
US8535721B2 (en) 2013-09-17
FR2754177B1 (fr) 1999-08-06
HRP970537A2 (en) 1998-08-31
NO991613L (no) 1999-04-06
HK1021939A1 (en) 2000-07-21
AU4560297A (en) 1998-05-05
HRP970537B1 (en) 2002-08-31
US20030157177A1 (en) 2003-08-21
IL128745A (en) 2004-05-12
DE69712100D1 (de) 2002-05-23
ATE216228T1 (de) 2002-05-15
IL128745A0 (en) 2000-01-31
ID24596A (id) 2000-07-27
IS1985B (is) 2005-02-15
EE03744B1 (et) 2002-06-17
CZ288876B6 (cs) 2001-09-12
AU731235B2 (en) 2001-03-29
RU2177315C2 (ru) 2001-12-27
MY120521A (en) 2005-11-30
FR2754177A1 (fr) 1998-04-10
TW508251B (en) 2002-11-01
DZ2316A1 (fr) 2002-12-28
ME00664B (me) 2007-06-04
SI0956010T1 (en) 2002-10-31
JP2000504038A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
ES2174293T3 (es) Microesferas farmaceuticas de acido valproico para la administracion oral.
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
ES2183555T3 (es) Formulaciones efervescentes.
ES2159591T3 (es) Composicion de liberacion controlada.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
AR018828A1 (es) Formulaciones efervescentes solidas de rapida desintegracion para administracion oral.
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
SV2002000520A (es) Derivados de pirazol ref. pcs10927aajr/bb
ES2178479T3 (es) Concentrado de principio activo con formoterol, apto para el almacenamiento.
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR032293A1 (es) Estuche farmaceutico
AR013117A1 (es) Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
TR199902175T2 (xx) Parasetamol i�eren yutma tableti.
ES2179533T3 (es) Formulacion de medicamento con liberacion controlada del principio activo.
ES2164310T3 (es) Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
PE68199A1 (es) Composicion farmaceutica de residencia gastrica
AR025351A1 (es) Agonistas retinoides selectivos par
ES2175827T3 (es) Formulaciones transmucosas de levosimendano.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 956010

Country of ref document: ES